Dec. 4 – 5, 2013
Redwood City, CA
Today is Giving Tuesday — the next T-day after Thanksgiving that bookends a weekend of spending that follows the one day we’re supposed to give thanks for what we already have.
Seems VCs were happy to give millions of dollars to startups, albeit not exactly altruistically. One of the most interesting, and most deserving companies we saw today was a really cool new medical tool: tumor paint. This “paint” helps doctors to literally see which cells are cancerous and which are healthy, so no extra healthy cells get the boot in surgery.
DataSift grabs $42M to grow its social data platform
Big data startup DataSift has closed a fresh $42 million round of funding, the company announced today. DataSift’s platform allows businesses and other organizations to extrapolate social data from across many popular social networking sites. It then interprets that data to be used in conjunction with enterprise services to give its clients a better handle on public opinion and help them better shape marketing messages. The new funding round, DataSift’s third, was led by Insight Venture Partners, with participation from existing investors Scale Venture Partners, Upfront Ventures, IA Ventures, Northgate Capital, Daher Capital, and Cendana Capital. Read the full story on VentureBeat.
Navabi snags funding to stay ahead of the ‘curve’
Navabi has raised $13.6 million (€10 million) for its site which sells plus size designer clothes for women. The German company claims to offer one of the largest assortments of designer fashion for plus size women in Europe and will use this funding to fuel international growth. Navabi said 30 percent of its revenue is already coming from the US and UK. Index Ventures led this round with participation from previous investors.
Tumor Paint helps doctors cut the cancers, not healthy tissue, from kids’ brains
On an MRI scan, cancer is easy enough to spot. But during surgery, these cells can look remarkably similar to the healthy ones, which are often cutout by accident. So Olson, a Seattle-based pediatric neuro-oncologist, set out to develop technology to help surgeons better differentiate between cancerous and healthy tissue. What he came up with is a new product called Tumor Paint, which illuminates cancer cells with fluorescent dye. Armed with promising early test results, the company received $9 million in fresh second round financing today from individual investors, primarily biotech executives, and parents of Olson’s patients. To date, Blaze Bioscience has raised $19 million. Read the full story on VentureBeat.